Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atrial Fibrillation and Lipid-related Indices in Japanese Men: An Age-matched Case-control Study.

In vivo (Athens, Greece)·2026
Same author

[Individual Differences in the Impact of Habitual Alcohol Drinking on Blood Pressure].

Nihon eiseigaku zasshi. Japanese journal of hygiene·2026
Same author

Combined Conventional Blood Biomarkers as Discriminators of Excessive Alcohol Consumption in Men: A Large-Scale Cross-Sectional Study.

Healthcare (Basel, Switzerland)·2026
Same author

Prognostic Value of the Hematometabolic Index for Incident Metabolic Syndrome: Findings From a Large Occupational Cohort of Japanese Men.

Cureus·2026
Same author

Comparative Analysis of the Oral Frailty Five-item Checklist and Oral Frailty Index-8 Tools in Assessing Oral Frailty and Their Association with Systemic Health Indicators.

JMA journal·2025
Same author

Gender Differences in the Associations Between Serum Urate and Cardiometabolic Risk Factors in Age-Matched Middle-Aged Japanese.

Women's health reports (New Rochelle, N.Y.)·2025

Related Experiment Video

Updated: Sep 9, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.0K

[Antithrombotic Action of Resveratrol: Particularly Regarding Inhibition of Platelet Aggregation].

Kazumi Ekawa1, Mikio Marumo1, Ichiro Wakabayashi1

  • 1Department of Preventive Medicine, Faculty of Medicine, Hyogo Medical University.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|August 31, 2025
PubMed
Summary

Resveratrol, found in red wine, and ethanol exhibit an additive effect in preventing platelet aggregation, a key factor in atherosclerosis. This compound offers multiple protective actions against cardiovascular disease.

Keywords:
antioxidant actionatherosclerotic cardiovascular diseasecapacitative Ca2+ entryplatelet aggregationred wineresveratrol

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

803

Related Experiment Videos

Last Updated: Sep 9, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.0K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

803

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Nutraceuticals

Background:

  • Ischemic heart disease prevention is linked to moderate red wine consumption, known as the French paradox.
  • Red wine contains polyphenols, such as resveratrol, and ethanol, which may contribute to its cardioprotective effects.
  • Platelets play a critical role in atherosclerosis development and thrombosis.

Purpose of the Study:

  • To investigate the effects of resveratrol and ethanol on platelet aggregation.
  • To elucidate the mechanisms by which resveratrol inhibits platelet function.
  • To assess the potential of resveratrol in preventing atherosclerosis and thrombosis.

Main Methods:

  • In vitro studies examining resveratrol's effect on platelet Ca2+ influx and aggregation.
  • Co-administration studies with resveratrol and ethanol to evaluate combined effects.
  • Analysis of resveratrol's antioxidant activity and its impact on platelet signaling pathways.

Main Results:

  • Resveratrol inhibited platelet aggregation and Ca2+ influx in a concentration-dependent manner.
  • Resveratrol and ethanol demonstrated an additive inhibitory effect on platelet aggregation.
  • Resveratrol's mechanisms include antioxidant action, inhibition of capacitative Ca2+ influx, and direct inhibition of cyclooxygenase-1 and phospholipase A2.

Conclusions:

  • Resveratrol possesses multiple anti-atherosclerotic and anti-thrombotic properties.
  • Resveratrol, in combination with ethanol, offers enhanced inhibition of platelet aggregation.
  • Resveratrol's multifaceted actions suggest its potential as a therapeutic agent for cardiovascular diseases.